Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M

CORCEPT THERAPEUTICS INC

2022-Q3 EPS reported $0.73 revenue$298,802,000

Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.
Tightened FY 2022 revenue guidance to $400-410M from prior range.
Cash and investments $401.2M at Sept 30, up from $382M at June 30.
Operating expenses $69.8M (+16.5% YoY) on clinical and commercial expansion.
Enrolling pivotal Phase 3 ROSELLA trial in ovarian cancer; GRATITUDE AIWG data expected Q4 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2022 results: revenue $101.7 million, net income $34.6 million, EPS $0.30. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $101.7 million
Net income: $34.6 million
EPS: $0.30
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue of $101.7 million, compared to $96.1 million in third quarter 2021 • Tightened 2022 revenue guidance of $400 – $410 million • Diluted net income per common share of $0.30, compared to $0.24 in third quarter 2021

View on SEC.gov

Browse all earnings releases →

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-22-028184

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.